Two- vs 8-Week Course of Radiotherapy for Prostate Cancer: 10-Year Follow-up
The phase III HYPO-RT-PC reported 10-year follow-up exploring shorter course radiotherapy for localized prostate cancer. The findings were presented at ESTRO 2025
Related Articles
Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARAN OTE trial, which evaluated the androgen…
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared…
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to…
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Surgery provides improved long-term survival for patients with pancreatic ductal adenocarcinoma, with a benefit of avoiding metastatic disease but a potential risk for postoperative morbidity…
First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-H Advanced Gastric/GEJ Cancer
In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose…
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with…
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
ASCO 2025: Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer
Results from the phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy…